De-Risk Oncology Discovery with Human-Relevant In Vivo, In Vitro & In Silico Models & Integrated Preclinical Platforms
Generate robust, decision-enabling datasets—from efficacy and pharmacology to translational models—designed to support confident progression toward IND submission.
Combine Cyagen's HUGO (Humanized Genomic Ortholog) models with NKG and humanized immune system (HIS) platforms to improve clinical predictability in oncology and immuno-oncology programs.
Combine Cyagen's HUGO (Humanized Genomic Ortholog) models with NKG and humanized immune system (HIS) platforms to improve clinical predictability in oncology and immuno-oncology programs.
Enable rapid efficacy and mechanism-of-action studies using validated CDX models and custom-engineered tumor cell lines tailored to your target and modality.
Collaborate with experienced scientific teams to design fit-for-purpose studies aligned with your biology, modality, and key development milestones
Featured Experts
Resources
Swags & Offers
Featured Experts
Joseph Wekselblatt is an experienced scientist who has studied visual capabilities in various species for over a decade. He holds a Bachelor's degree in Cognitive Science from Brown University and a PhD in Neurobiology from the University of Oregon. After completing his PhD, he worked as a Postdoctoral Researcher at Caltech until 2023, when he joined Cyagen as a Senior Scientific Business Development Manager.
Dr. Jenny Shan (MD, PhD) brings decades of R&D experience from industry leaders like Regeneron, Moderna, J&J, EQRx, Apogee, and Curie.Bio.
Her expertise spans diverse modalities—antibodies, small molecules, ADCs, CAR-T, mRNA, siRNA, peptides, oligonucleotides, AAV, and gene editing—across oncology, immunology, cardiovascular, neuroscience, and ophthalmology.
As a strategic pipeline architect, Dr. Shan has advanced multiple programs from discovery to clinical development. She supported the IND and regulatory approvals for numerous biologics, contributing to blockbuster drugs such as Eylea, Dupixent, Carvykti, and Rybrevant.
Ivan is an accomplished scientific leader with extensive experience at the intersection of biomedical research and commercial innovation. He holds a PhD from Monash University's Australian Regenerative Medicine Institute, following a First-Class Honours degree in Medical Bioscience.
With a career spanning Europe and Asia, Ivan has led international teams, developed new business territories, and built partnerships with CRO and pharmaceutical organisations. His combination of scientific expertise and commercial strategy will support Cyagen's continued expansion and success across global markets.
Spotlight Presentation
Swags & Offers
